{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:02:52Z","timestamp":1789736572268,"version":"4.0.1"},"reference-count":29,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/03007995.2022.2059976","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:20:33Z","timestamp":1648700433000},"page":"1295-1303","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma"],"prefix":"10.1080","volume":"38","author":[{"given":"George","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, George Washington University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cockrum","sequence":"additional","affiliation":[{"name":"Ipsen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"CIT0001","unstructured":"Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2476"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4846"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919875568"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439\u2013457. Published 2021 Apr 1. doi:10.6004\/jnccn.2021.0017","DOI":"10.6004\/jnccn.2021.0017"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1615879"},{"key":"CIT0008","unstructured":"U.S. Food and Drug Administration, FDA\u2019s sentinel initiative \u2013 background; 2020 [cited 2020 Mar 23]. Available from: https:\/\/www.fda.gov\/safety\/fdas-sentinel-initiative\/"},{"key":"CIT0009","unstructured":"U.S. Food and Drug Administration, Sentinel initiative; 2008 [cited 2020 Mar 23]. Available from: https:\/\/www.sentinelinitiative.org\/."},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.17.00033"},{"issue":"2","key":"CIT0012","first-page":"33","volume":"3","author":"Schroeder A.","year":"2017","journal-title":"J Clin Pathways"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07110-x"},{"key":"CIT0014","unstructured":"U.S. Department of Health and Human Services, Common terminology criteria for adverse events (CTCAE) version 4.0 (v4.03): National Institutes of Health; 2010."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605374"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i33.4533"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1875-1"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920944052"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1159\/000091312"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.848208"},{"key":"CIT0022","unstructured":"Hirsch J, Pelizzari P, Cockrum P. Treatment patterns, survival rate, and total costs by line of therapy for FDA-approved\/NCCN category 1 treatments for Medicare patients with metastatic pancreatic cancer(Poster C5). AMCP Nexus; 2019 October 29 to November 1; National Harbor, MD."},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e18357"},{"key":"CIT0024","doi-asserted-by":"crossref","unstructured":"Muldoon LD, Hirsch J, Dieguez G, et\u00a0al. Comparing service utilization and costs for Medicare FFS patients with metastatic pancreatic cancer by chemotherapy regimen and line of therapy (Poster PCN302). ISPOR; 2019 May 18\u201322; New Orleans, LA.","DOI":"10.1016\/j.jval.2019.04.420"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27490"},{"key":"CIT0026","unstructured":"Dieguez G, Surinach A, Mercer D, et\u00a0al. Real-world rates of hematologic laboratory abnormalities and associated cost among metastatic pancreatic cancer therapeutic regimens (J1). American Society for Clinical Oncology \u2013 Gastrointestinal Cancers Symposium; 2020 January 23\u201325; San Francisco, CA."},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Herrera-Restrepo O, Ferrufino CP, Bilir SP, et\u00a0al. Budget impact in the USA of liposomal irinotecan as a post-gemcitabine treatment option for patients with metastatic pancreatic adenocarcinoma (mPC) (poster PCN80). ISPOR; 2019 May 18\u201322; New Orleans, LA.","DOI":"10.1016\/j.jval.2019.04.204"},{"key":"CIT0028","unstructured":"Hirsch J, Dieguez G, Cockrum P. The cost of adverse events for FDA-approved\/NCCN category 1 treatments for medicare fee-for-service patients with metastatic pancreatic cancer (poster 4-138). ASHP Midyear Clinical Meeting; 2019 December 8\u201312; Las Vegas, NV."},{"key":"CIT0029","unstructured":"Prescott J, Pelletier V, Schilling A, et al. The state of the management of metastatic pancreatic cancer \u2013 a focus on recent real-world clinical & economic evidence with liposomal irinotecan. Clinical Brief; 2020 [cited April 7]. Available from: https:\/\/ajmc.s3.amazonaws.com\/_media\/_pdf\/ajmc_a911_metastaticpancreaticcancer_clinicalbrief_web.pdf."}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2022.2059976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T11:52:31Z","timestamp":1659959551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2022.2059976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/03007995.2022.2059976"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2022.2059976","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}